Drug Profile
Research programme: vaginal infection antimicrobial peptides - Armata Pharmceuticals
Latest Information Update: 14 May 2019
Price :
$50
*
At a glance
- Originator C3 Jian
- Developer C3J Therapeutics
- Class Peptide fragments
- Mechanism of Action Peptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Candidiasis; Vaginitis
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 18 Apr 2018 Discontinued - Preclinical for Candidiasis in USA (unspecified route) (C3J Therapeutics pipeline, April 2018)
- 18 Apr 2018 Discontinued - Preclinical for Vaginitis in USA (unspecified route) (C3J Therapeutics pipeline, April 2018)